Skip to main content
Clinical Trials/CTRI/2022/04/041704
CTRI/2022/04/041704
Recruiting
Phase 3

Randomized Controlled Trial of the Efficacy of ProGenX in the Resolution of Post-COVID Fatigue & Immune status

ihar Ranjan Pradhan0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
ihar Ranjan Pradhan
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
ihar Ranjan Pradhan

Eligibility Criteria

Inclusion Criteria

  • Males or non\-pregnant, non\-lactating females aged \- 18 to 75 years (both inclusive);
  • RT\-PCR confirmed diagnosis of COVID\-19 at any time followed by an RT\-PCR negative test;
  • Patients experiencing fatigue and muscle weakness;
  • Able to take the drug orally and comply with study procedures;
  • Women of childbearing potential with a negative urine pregnancy test.

Exclusion Criteria

  • Prior known respiratory distress (RR\-30 times/min);
  • Finger oxygen saturation \< 90% in a resting state,
  • Arterial partial pressure of oxygen(pao2\)/concentration of oxygen inhalation (Fio2\) \<300 mmHg;
  • Respiratory failure or on mechanical ventilation,
  • ICU needed for other organ failure;
  • Patients with other viral pneumonia;
  • Patients unable to take food or drugs due to coma or intestinal obstruction;
  • Consumption of other oral probiotic supplements during the trial;
  • Patients with severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected;
  • Blood diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials